Biblio
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. Am J Hematol. 2023.
. Endophthalmitis, Cutaneous Nodules, and Brain Lesions in Stem Cell Transplant Recipient. Clin Infect Dis. 2023;77(8):1212-1215.
. HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther. 2022.
Mycophenolate mofetil is associated with inferior overall survival in cytomegalovirus seropositive patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Haematologica. 2024.
A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv. 2019;3(23):4117-4130.
Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. Front Med (Lausanne). 2015;2:89.
. THE OPTIMAL KIR DONOR - WE CAN RECOGNIZE, BUT CAN WE SEARCH?. Biol Blood Marrow Transplant. 2018.
. Optimizing the Conditioning Regimen for HCT in Myelofibrosis: Long-term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant. 2020.
Post-Transplantation Cyclophosphamide vs Tacrolimus and Methotrexate Graft-versus-Host Disease Prophylaxis For HLA-Matched Donor Transplantation. Transplant Cell Ther. 2022.
A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Bone Marrow Transplant. 2023.